US women’s health focused drugmaker Organon (NYSE: OGN) yesterday revealed disappointing results from the Phase II ELENA ...

The chronic kidney disease (CKD) anemia market across the seven major markets (7MM) is forecast to grow at a compound annual ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

Under the terms of the deal, HanchorBio will receive an upfront payment of $10 million, with additional payments tied to ...

Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with ...

A federal judge has blocked the US Department of Health and Human Services from moving forward with a major workforce ...

US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

A clinical-stage biotech company based in Los Altos, California, developing treatments for kidney diseases.